Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tree MATA MPL in Tree Pollen Allergy
NCT00118625Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Jul 2005
- Modality
- Prophylactic Vaccines, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tree MATA MPL in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Allergy Therapeutics PLC. Primary endpoint: Immunological response to Tree MATA MPL versus Tree MATA (birch specific). Started Jul 2005; status: completed.
02
Drugs
Tree MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00118625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118625.